Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | TLR4 | O00206 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979699 | 0.89 | HSP90AB1 (0.44) | MAPTHSP90AB1LRRK2TSHRMAPK1 | |
| SCHEMBL4976253 | 0.87 | KDM4E (0.48) | MAPTHSP90AB1TSHRCCR3 | |
| SCHEMBL4978525 | 0.86 | HSP90AB1 (0.52) | MAPTHSP90AB1TSHR | |
| SCHEMBL4978047 | 0.86 | HSP90AB1 (0.52) | MAPTHSP90AB1TSHRTLR9TLR7 | |
| SCHEMBL4979675 | 0.86 | ALDH1A1 (0.48) | MAPTHSP90AB1TSHRMAPK1HSD17B10 | |
| SCHEMBL4979445 | 0.86 | HSP90AB1 (0.49) | MAPTHSP90AB1LRRK2HSP90AA1 | |
| SCHEMBL4976963 | 0.85 | MAPT (0.49) | MAPTHSP90AB1TSHR | |
| SCHEMBL4977156 | 0.85 | HSP90AB1 (0.43) | MAPTHSP90AB1CCR3 | |
| SCHEMBL4973690 | 0.84 | HSP90AB1 (0.43) | HSP90AB1MAPK1HSP90AA1CCR3TLR4 | |
| SCHEMBL4978128 | 0.84 | DGAT1 (0.46) | MAPTHSP90AB1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | MAPT 2301/4885HSP90AB1 2652/4885LRRK2 1855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.